Format

Send to

Choose Destination
Chest. 2012 Feb;141(2):396-405. doi: 10.1378/chest.11-0495. Epub 2011 Aug 11.

Systemic biomarkers in exacerbations of COPD: the evolving clinical challenge.

Author information

1
Service de Pneumologie et Rehabilitation Respiratoire, Hôpital de Rolle, Switzerland.
2
Clinic for Pulmonary Medicine and Respiratory Cell Research, University Hospital, Basel, Switzerland.
3
Second Respiratory Medicine Department, University of Athens Medical School, Athens, Greece.
4
Second Respiratory Medicine Department, University of Athens Medical School, Athens, Greece. Electronic address: ktk@otenet.gr.

Abstract

BACKGROUND:

Exacerbations of COPD (ECOPD) remain a major cause of mortality and morbidity. Despite advances in the understanding of their pathophysiology, their assessment relies primarily on clinical presentation, which can be variable and difficult to predict. A large number of biomarkers already have been assessed in this context, and some appear to be promising.

METHODS:

An online search for articles published until December 2010 was conducted using three terms for ECOPD, five terms for biomarkers, and five terms for the sampling method. Biomarkers were evaluated for their potential role in the establishment and confirmation of the diagnosis of ECOPD, the evaluation of etiology and severity, the prediction of prognosis, and the guidance of treatment decisions.

RESULTS:

Several systemic biomarkers have been measured in the context of ECOPD, and most have been found to increase at ECOPD onset and to subside during the course of exacerbations. Correlations have been reported among these biomarkers, but direct associations with clinical variables have been more difficult to establish. Although there are several limitations yet to be addressed, some of the biomarkers, most notably C-reactive protein for the identification of an ECOPD and procalcitonin for antibiotic guidance, may provide clinically relevant information.

CONCLUSIONS:

So far, no single biomarker has been able to gain wide acceptance, but some provide clinically useful information. The evaluation of such biomarkers in large decision-making studies is expected to become an area of intense investigation in the near future.

PMID:
21835899
DOI:
10.1378/chest.11-0495
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center